2 active not recruiting, 2 recruiting, 2 unknown, 1 completed. 5 Phase 1, 1 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Active not recruiting 2, Completed 1, Recruiting 1, Terminated 1 |
| Early Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Lymphomas Non-Hodgkin's B-Cell: new trials by email Literature Review of Lymphomas Non-Hodgkin's B-Cell trials Research Report on Lymphomas Non-Hodgkin's B-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment INT2104 - Lymphomas Non-Hodgkin's B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 | Active not recruiting | Kite, A Gilead Company | 10 | 2024-09-20 | 2026-09-08 |
| T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) EB103 - B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins | Phase 1 / Phase 2 | Recruiting | Estrella Immunopharma, Inc. | 27 | 2024-06-01 | 2026-10-01 |
| Obinutuzumab in Chinese Real-world Patients With iNHL Obinutuzumab - Lymphomas Non-Hodgkin's B-Cell | Unknown | Affiliated Hospital of Nantong University | 400 | 2023-07-20 | 2023-08-01 | |
| ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) WZTL002-1 (1928T2z CAR-T cells), Cyclophosphamide and Fludarabine lymphodepleting chemotherapy - Lymphomas Non-Hodgkin's B-Cell, Diffuse Large B-cell Lymphoma (DLBCL) | Phase 1 | Active not recruiting | Malaghan Institute of Medical Research | 30 | 2019-10-11 | 2024-08-21 |
| Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma ET190L1 ARTEMIS™ T cells - Lymphomas Non-Hodgkin's B-Cell | Phase 1 | Terminated | Eureka Therapeutics Inc. | 4 | 2018-04-04 | 2019-02-04 |
| Long-term Follow-up Study of Patients Receiving CAR-T Cells Long-Term Follow-Up of Participants who Received CAR-T cells - Chronic Lymphocytic Leukemia, Lymphomas Non-Hodgkin's B-Cell | Recruiting | Medical College of Wisconsin | 500 | 2017-12-01 | 2025-11-10 | |
| Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study Avelumab - Lymphomas Non-Hodgkin's B-Cell | Early Phase 1 | Unknown | Austin Health | 28 | 2017-07-21 | 2024-07-30 |
| CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma CD19 CAR T cells - Lymphomas Non-Hodgkin's B-Cell, Relapse | Phase 1 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2017-06-08 | 2026-02-11 |
Lymphoma, B-Cell (8) · Lymphoma (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Mantle-Cell (2) · Recurrence (2) · Burkitt Lymphoma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, Primary Effusion (1) · Multiple Myeloma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hemic and Lymphatic Diseases (8) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphatic Diseases (8) · Lymphoproliferative Disorders (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Lymphoma, Non-Hodgkin (7) · Lymphoma (6) · Disease Attributes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Hematologic Diseases (2) · Leukemia (2) · Leukemia, Lymphoid (2)
Cyclophosphamide (1) · avelumab (1) · obinutuzumab (1)
Affiliated Hospital of Nantong University (1) · Austin Health (1) · Estrella Immunopharma, Inc. (1) · Eureka Therapeutics Inc. (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Kite, A Gilead Company (1) · Malaghan Institute of Medical Research (1) · Medical College of Wisconsin (1)
United States (3) · Australia (2) · China (2) · New Zealand (1) · Spain (1)
David A Rizzieri, MD (1) · Dehui Zou, Dr. (1) · Eliza Hawkes, MD (1) · Nirav Shah (1) · Pei Wang, PhD (1) · Robert Weinkove, MBBS, PhD (1)
PMID 32175617, PMID 34515338, PMID 34531588, PMID 40960310
2023 (1)